[go: up one dir, main page]

MX2023010958A - Agentes de arn modificados con efecto reducido fuera de la diana. - Google Patents

Agentes de arn modificados con efecto reducido fuera de la diana.

Info

Publication number
MX2023010958A
MX2023010958A MX2023010958A MX2023010958A MX2023010958A MX 2023010958 A MX2023010958 A MX 2023010958A MX 2023010958 A MX2023010958 A MX 2023010958A MX 2023010958 A MX2023010958 A MX 2023010958A MX 2023010958 A MX2023010958 A MX 2023010958A
Authority
MX
Mexico
Prior art keywords
dsrna
ligand
reduced
modified rna
target effect
Prior art date
Application number
MX2023010958A
Other languages
English (en)
Inventor
Stuart Milstein
Klaus Charisse
Alfica Sehgal
Donald Foster
Muthiah Manoharan
Christopher Theile
Maja Janas
Vasant R Jadhav
Muthusamy Jayaraman
Alexander V Kel'in
Shigeo Matsuda
Jayaprakash K Nair
Martin A Maier
Kallanthottathil G Rajeev
Christopher Brown
Mark K Schlegel
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60888585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023010958(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of MX2023010958A publication Critical patent/MX2023010958A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un aspecto de la presente invención se refiere a un agente de ARN de doble cadena (ARNdc) capaz de inhibir la expresión de un gen diana. La cadena no codificante de la molécula de ARNdc comprende al menos un nucleótido térmicamente desestabilizante que se encuentra en una región semilla; el ARNdc comprende al menos cuatro modificaciones de 2'-fluoro, y la cadena codificante de la molécula de ARNdc comprende un ligando, en donde el ligando es un ligando de ASGPR. Otros aspectos de la invención se refieren a composiciones farmacéuticas que comprenden estas moléculas de ARNdc adecuadas para su uso terapéutico, y a métodos para inhibir la expresión de un gen diana al administrar estas moléculas de ARNdc, por ejemplo, para el tratamiento de varias afecciones patológicas.
MX2023010958A 2016-11-23 2019-05-17 Agentes de arn modificados con efecto reducido fuera de la diana. MX2023010958A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425907P 2016-11-23 2016-11-23
US201762548589P 2017-08-22 2017-08-22
US201762561514P 2017-09-21 2017-09-21

Publications (1)

Publication Number Publication Date
MX2023010958A true MX2023010958A (es) 2023-12-07

Family

ID=60888585

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005816A MX2019005816A (es) 2016-11-23 2017-11-22 Agentes de arn modificados con efecto reducido fuera de la diana.
MX2023010958A MX2023010958A (es) 2016-11-23 2019-05-17 Agentes de arn modificados con efecto reducido fuera de la diana.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019005816A MX2019005816A (es) 2016-11-23 2017-11-22 Agentes de arn modificados con efecto reducido fuera de la diana.

Country Status (11)

Country Link
US (3) US11504391B1 (es)
EP (1) EP3544617A4 (es)
JP (3) JP7288852B2 (es)
KR (2) KR20240035907A (es)
CN (2) CN117757791A (es)
AU (3) AU2017363892B2 (es)
CA (1) CA3044598A1 (es)
IL (2) IL266780B1 (es)
MX (2) MX2019005816A (es)
SG (1) SG10201913786SA (es)
WO (1) WO2018098328A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107273A (ko) 2015-05-06 2025-07-11 알닐람 파마슈티칼스 인코포레이티드 인자 ＸＩＩ(하게만 인자)(Ｆ12), 칼리크레인 Ｂ, 혈장(플레처 인자) 1(ＫＬＫＢ1) 및 키니노겐 1(ＫＮＧ1) ｉＲＮＡ 조성물 및 그의 이용 방법
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
US11504391B1 (en) 2016-11-23 2022-11-22 Alnylam Pharmaceuticals, Inc. Modified RNA agents with reduced off-target effect
FR3060947B1 (fr) * 2016-12-28 2025-12-26 Ynsect Procede de traitement d'insectes comprenant la separation des cuticules de la partie molle des insectes puis la separation de la partie molle en trois fractions
EP3645546A4 (en) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. CHIRAL PHOSPHORAMIDITIS AUXILIARIES AND THEIR METHODS OF USE
US20200208150A1 (en) * 2017-07-07 2020-07-02 Alnylam Pharmaceuticals, Inc. METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)
EP3720448A4 (en) 2017-12-06 2021-11-03 Avidity Biosciences, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
WO2019217397A2 (en) * 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for improving strand biased
MX2020011570A (es) 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
AU2019270152B2 (en) 2018-05-16 2025-05-08 Alnylam Pharmaceuticals, Inc. Modified RNA agents with reduced off-target effect
JP7379387B2 (ja) 2018-06-05 2023-11-14 エフ． ホフマン－ラ ロシュ アーゲー Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド
MX2021000404A (es) 2018-07-13 2021-03-25 Hoffmann La Roche Oligonucleotidos para modular la expresion de rtel1.
CA3106701A1 (en) * 2018-08-13 2020-02-20 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
LT3897672T (lt) 2018-12-20 2023-11-10 Vir Biotechnology, Inc. Kombinuota hbv terapija
JP7725370B2 (ja) 2019-04-03 2025-08-19 ブリストル－マイヤーズ スクイブ カンパニー Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用
JP7497061B2 (ja) * 2019-07-16 2024-06-10 国立大学法人 東京大学 Ｒｎａ分子、キメラ型ｎａ分子、二本鎖ｒｎａ分子、および二本鎖キメラ型ｎａ分子
CN114555621B (zh) 2019-08-15 2025-10-28 Ionis制药公司 键修饰的寡聚化合物及其用途
JP7805286B2 (ja) * 2019-09-03 2026-01-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｌｅｃｔ２遺伝子の発現を阻害するための組成物および方法
WO2021096763A1 (en) * 2019-11-13 2021-05-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
CN114867856A (zh) 2019-12-19 2022-08-05 豪夫迈·罗氏有限公司 Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
JP2023506540A (ja) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
CN114829601A (zh) 2019-12-19 2022-07-29 豪夫迈·罗氏有限公司 Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
CN115516091A (zh) 2019-12-19 2022-12-23 豪夫迈·罗氏有限公司 Cops3抑制剂用于治疗乙型肝炎病毒感染的用途
JP7634542B2 (ja) 2019-12-19 2025-02-21 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
CA3162845A1 (en) * 2019-12-23 2021-07-01 Anastasia Khvorova Oligonucleotides for tissue specific gene expression modulation
CN114828852A (zh) 2019-12-24 2022-07-29 豪夫迈·罗氏有限公司 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
CA3163490A1 (en) 2019-12-24 2021-07-01 F. Hoffman-La Roche Ag Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
BR112022019137A2 (pt) 2020-03-27 2023-01-31 Avidity Biosciences Inc Composições e métodos de tratamento de distrofia muscular
EP4150084A1 (en) 2020-05-11 2023-03-22 Genentech, Inc. Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
JP2023527693A (ja) 2020-05-11 2023-06-30 ジェネンテック， インコーポレイテッド 神経疾患を治療するための補体成分ｃ１ｒ阻害剤、並びに関連する組成物、システム、及びそれを使用する方法
EP4149486A1 (en) 2020-05-11 2023-03-22 Genentech, Inc. Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
TW202214858A (zh) * 2020-08-04 2022-04-16 大陸商上海拓界生物醫藥科技有限公司 脫靶活性降低的修飾siRNA
JP2023538630A (ja) 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
WO2022061108A2 (en) * 2020-09-17 2022-03-24 Q-State Biosciences, Inc. Therapeutic compositions for treating pain via multiple targets
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
WO2022154123A1 (ja) * 2021-01-15 2022-07-21 国立大学法人 東京大学 Ｒｎａ分子、キメラ型ｎａ分子、二本鎖ｒｎａ分子、および二本鎖キメラ型ｎａ分子
EP4175965B1 (en) 2021-01-30 2024-03-13 E-Therapeutics plc Conjugated oligonucleotide compounds, methods of making and uses thereof
TW202305131A (zh) 2021-02-12 2023-02-01 美商艾拉倫製藥股份有限公司 用於治療或預防超氧歧化酶１－（ＳＯＤ１－）相關的神經退化疾病的超氧歧化酶１（ＳＯＤ１）ｉＲＮＡ組成物及其使用方法
EP4314296A2 (en) 2021-03-29 2024-02-07 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
CN115261385A (zh) * 2021-04-30 2022-11-01 纳肽得有限公司 对小核酸进行序列修饰的方法及其应用
JP2024534766A (ja) 2021-08-13 2024-09-26 アルナイラム ファーマシューティカルズ， インコーポレイテッド 第ＸＩＩ因子（Ｆ１２）ｉＲＮＡ組成物およびその使用方法
CA3231330A1 (en) 2021-09-16 2023-03-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
MX2024003519A (es) 2021-09-24 2024-04-01 Alnylam Pharmaceuticals Inc Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
CN118284695A (zh) 2021-11-11 2024-07-02 豪夫迈·罗氏有限公司 用于治疗hbv的药物组合
IL312811A (en) 2021-11-16 2024-07-01 Shanghai Argo Biopharmaceutical Co Ltd Composition and method for inhibiting angiotensinogen (agt) protein expression
CN119095603A (zh) 2021-12-17 2024-12-06 豪夫迈·罗氏有限公司 用于调节rtel1和fubp1的寡核苷酸的组合
WO2023131170A1 (zh) * 2022-01-05 2023-07-13 大睿生物医药科技(上海)有限公司 具有核苷酸类似物的双链rna
WO2024098061A2 (en) 2022-11-04 2024-05-10 Genkardia Inc. Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
EP4619524A1 (en) 2022-11-18 2025-09-24 Genkardia Inc. Methods and compositions for preventing, treating, or reversing cardiac diastolic dysfunction
WO2024140101A1 (zh) * 2022-12-28 2024-07-04 北京炫景瑞医药科技有限公司 修饰的双链寡核苷酸分子、修饰的双链寡核苷酸缀合物及其用途
US20240254485A1 (en) * 2023-01-13 2024-08-01 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof
EP4669749A1 (en) 2023-02-21 2025-12-31 Vib Vzw OLIGONUCLEOTIDES TO MODULATE SYNAPTOGYRIN-3 EXPRESSION
EP4669750A2 (en) 2023-02-21 2025-12-31 Vib Vzw SYNAPTOGYRIN-3 EXPRESSION INHIBITORS
EP4669752A1 (en) * 2023-02-22 2025-12-31 Altamira Therapeutics AG KRAS COMPOSITIONS AND INHIBITION METHODS FOR THE TREATMENT OF A DISEASE
WO2025067351A2 (en) 2023-09-27 2025-04-03 Neuro3 Therapeutics, Inc. Novel sirna constructs, therapeutics, and modifications
WO2025196505A2 (en) 2024-03-22 2025-09-25 Takeda Pharmaceutical Company Limited Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression
CN119410644A (zh) * 2025-01-08 2025-02-11 北京安龙生物医药有限公司 修饰的双链寡核苷酸及其缀合物和组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1745062T3 (da) 2004-04-22 2014-08-11 Regado Biosciences Inc Forbedrede modulatorer af koagulationsfaktorer
EP1681347A1 (en) * 2005-01-18 2006-07-19 Metanomics GmbH & Co. KGaA Improved methods for double-stranded RNA mediated gene silencing
CA2644347C (en) * 2006-03-23 2017-05-30 Santaris Pharma A/S Small internally segmented interfering rna
US20140170191A1 (en) 2008-10-23 2014-06-19 Hemispher Biopharma, Inc. Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
JP2012528596A (ja) * 2009-06-03 2012-11-15 ダイセルナ ファーマシューティカルズ， インコーポレイテッド ペプチドダイサー基質剤およびその特異的な遺伝子発現阻害のための方法
WO2011109427A2 (en) * 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Improving the biological activity of sirna through modulation of its thermodynamic profile
US10913767B2 (en) * 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
CN103502449B (zh) * 2010-12-02 2016-08-10 关键基因股份有限公司 用寡核苷酸靶向改变dna
CN103958519A (zh) * 2011-07-19 2014-07-30 爱达荷州大学 用于靶向核酸的探针和方法的实施方式
PL2999785T3 (pl) * 2013-05-22 2018-09-28 Alnylam Pharmaceuticals, Inc. Kompozycje iRNA Serpina1 i sposoby ich zastosowania
EP3052628B1 (en) 2013-10-04 2020-02-26 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the alas1 gene
AU2015252895B2 (en) * 2014-05-01 2021-07-15 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
AU2015364508A1 (en) 2014-12-18 2017-07-06 Alnylam Pharmaceuticals, Inc. ReversirTM compounds
US11504391B1 (en) 2016-11-23 2022-11-22 Alnylam Pharmaceuticals, Inc. Modified RNA agents with reduced off-target effect
JP7761558B2 (ja) 2019-10-11 2025-10-28 アルニラム ファーマスーティカルズ インコーポレイテッド 修飾オリゴヌクレオチド

Also Published As

Publication number Publication date
US11504391B1 (en) 2022-11-22
CN117757791A (zh) 2024-03-26
IL323679A (en) 2025-11-01
CN110582283A (zh) 2019-12-17
JP2025168400A (ja) 2025-11-07
WO2018098328A1 (en) 2018-05-31
IL266780B1 (en) 2025-11-01
JP7288852B2 (ja) 2023-06-08
KR20190086001A (ko) 2019-07-19
EP3544617A4 (en) 2020-08-05
SG10201913786SA (en) 2020-03-30
AU2017363892B2 (en) 2023-06-15
US20230256001A1 (en) 2023-08-17
JP2023053963A (ja) 2023-04-13
CA3044598A1 (en) 2018-05-31
IL266780A (en) 2019-08-29
AU2023226646A1 (en) 2023-11-16
EP3544617A1 (en) 2019-10-02
AU2023226646B2 (en) 2025-01-23
MX2019005816A (es) 2019-10-07
KR20240035907A (ko) 2024-03-18
NZ753920A (en) 2024-10-25
AU2025202185A9 (en) 2025-05-15
JP2019535288A (ja) 2019-12-12
CN110582283B (zh) 2024-01-02
AU2025202185A1 (en) 2025-04-17
KR102645243B1 (ko) 2024-03-11
AU2017363892A1 (en) 2019-06-13
US20250205272A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
MX2023010958A (es) Agentes de arn modificados con efecto reducido fuera de la diana.
SG10201903290YA (en) Modified double-stranded rna agents
MX385869B (es) Agentes de iarn modificados.
WO2019217397A3 (en) Compositions and methods for improving strand biased
IL290566B1 (en) Preparations and methods for preventing lipoprotein A gene expression
Wu et al. Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma
HRP20201200T1 (hr) OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
CR20220468A (es) AGENTES DE iARN PARA INFECCION CAUSADA POR EL VIRUS DE LA HEPATITIS B (Divisional 2019-0056)
SG171676A1 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
WO2009105260A3 (en) Ultra-small rnas as toll-like receptor-3 antagonists
BR112017013597A2 (pt) molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença.
MX2015011943A (es) Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
PH12013501955A1 (en) Viral inhibitor composition for in vivo therapeutic use
MX2023008469A (es) Oligonucleotidos de doble hebra modificados.
RU2014101547A (ru) Апоптоз-индуцирующее средство
BR112014010134A2 (pt) inibição da expressão genética viral
MX2025003172A (es) Agente de arni modificado especifico y composicion
BR112018010736A2 (pt) oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos
MX2021010255A (es) Oligonucleotidos que interferen con proteina de retraso mental de x fragil y metodos para usar los mismos.
WO2020117840A3 (en) Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions
EA201991254A1 (ru) Модифицированные средства на основе рнк, характеризующиеся пониженным нецелевым эффектом
HK1240264A1 (en) Modified double-stranded rna agents
MX2021010631A (es) Agentes de iarn modificados.